Cinacalcet hydrochloride for the treatment of hyperparathyroidism

Bibliography

• Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575-80
   PubMed Web of Science ®Google Scholar
• Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995;333:234-40
   PubMedGoogle Scholar
• Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 2007;3:122-33
   PubMedGoogle Scholar
• Breitwieser GE, Miedlich SU, Zhang M. Calcium sensing receptors as integrators of multiple metabolic signals. Cell Calcium 2004;35:209-16
   PubMed Web of Science ®Google Scholar
• Goodman WG, Belin T, Gales B, et al. Calcium-regulated parathyroid hormone release in patients with mild or advanced secondary hyperparathyroidism. Kidney Int 1995;48:1553-8
   Google Scholar
• Felsenfeld AJ, Rodriguez M, Aguilera-Tejero E. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol 2007;2:1283-305
   Google Scholar
• Takeyama K, Kitanaka S, Sato T, et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 1997;277:1827-30
   PubMed Web of Science ®Google Scholar
• Potts JT. Parathyroid hormone: past and present. J Endocrinol 2005;187:311-25
   PubMed Web of Science ®Google Scholar
• Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990;86:1313-19
   PubMed Web of Science ®Google Scholar
• Delmez JA, Tindira C, Grooms P, et al. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989;83:1349-55
   PubMed Web of Science ®Google Scholar
• Hebert SC, Brown EM, Harris HW. Role of the Ca(2+)-sensing receptor in divalent mineral ion homeostasis. J Exp Biol 1997;200:295-302
   PubMed Web of Science ®Google Scholar
• Rodriguez ME, Almaden Y, Canadillas S, et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 2007;292:F1390-5
   PubMed Web of Science ®Google Scholar
• Brown EM. Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens 1993;2:541-51
   PubMedGoogle Scholar
• Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005;288:F253-64
   PubMed Web of Science ®Google Scholar
• Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-43
   PubMed Web of Science ®Google Scholar
• Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328-36
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
   PubMed Web of Science ®Google Scholar
• Dvorak MM, Siddiqua A, Ward DT, et al. Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc Natl Acad Sci USA 2004;101:5140-5
   PubMed Web of Science ®Google Scholar
• Theman TA, Collins MT. The role of the calcium-sensing receptor in bone biology and pathophysiology. Curr Pharm Biotechnol 2009;10:289-301
   Web of Science ®Google Scholar
• Molostvov G, James S, Fletcher S, et al. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 2007;293:F946-55
   PubMed Web of Science ®Google Scholar
• Brown EM, Katz C, Butters R, Kifor O. Polyarginine, polylysine, and protamine mimic the effects of high extracellular calcium concentrations on dispersed bovine parathyroid cells. J Bone Miner Res 1991;6:1217-25
   Google Scholar
• Ray K, Northup J. Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human Ca2+ receptor. J Biol Chem 2002;277:18908-13
   PubMedGoogle Scholar
• Harrington PE, Fotsch C. Calcium sensing receptor activators: calcimimetics. Curr Med Chem 2007;14:3027-34
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040-5
   PubMed Web of Science ®Google Scholar
• Martin KJ, Pickthorn K, Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int 2014;85:191-7
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004;308:627-35
   PubMed Web of Science ®Google Scholar
• Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 2009;48:303-11
   PubMed Web of Science ®Google Scholar
• Fox J, Lowe SH, Petty BA, Nemeth EF. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999;290:473-9
   PubMed Web of Science ®Google Scholar
• Conigrave AD, Lok HC. Activation of renal calcium and water excretion by novel physiological and pharmacological activators of the calcium-sensing receptor. Clin Exp Pharmacol Physiol 2004;31:368-71
   Google Scholar
• Dimke H, Desai P, Borovac J, et al. Activation of the Ca(2+)-sensing receptor increases renal claudin-14 expression and urinary Ca(2+) excretion. Am J Physiol Renal Physiol 2013;304:F761-9
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7
   PubMed Web of Science ®Google Scholar
• Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 2009;53:197-207
   PubMed Web of Science ®Google Scholar
• Coyne DW. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract Nephrol 2008;4:364-5
   Google Scholar
• Cooper K, Quarles D, Kubo Y, et al. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients. Nephron Clin Pract 2012;121:c124-30
   Google Scholar
• Miller G, Davis J, Shatzen E, et al. Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD. Nephrol Dial Transplant 2012;27:2198-205
   Google Scholar
• Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
   PubMed Web of Science ®Google Scholar
• Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007;92:3803-8
   PubMed Web of Science ®Google Scholar
• Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med 2011;365:2389-97
   PubMed Web of Science ®Google Scholar
• Padhi D, Harris RZ, Salfi M, Sullivan JT. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara). Clin Pharmacokinet 2005;44:509-16
   PubMed Web of Science ®Google Scholar
• Padhi D, Harris RZ, Salfi M, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study. Clin Drug Investig 2008;28:635-43
   PubMed Web of Science ®Google Scholar
• Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs 2005;65:271-81
   Google Scholar
• Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009(113):S1-130
   Google Scholar
• Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1423-9
   PubMed Web of Science ®Google Scholar
• Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009;24:1506-23
   PubMed Web of Science ®Google Scholar
• Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701
   PubMed Web of Science ®Google Scholar
• Coen G, Manni M, Mantella D, et al. Are PTH serum levels predictive of coronary calcifications in haemodialysis patients? Nephrol Dial Transplant 2007;22:3262-7
   Google Scholar
• London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-40
   PubMed Web of Science ®Google Scholar
• Barsotti G, Cupisti A, Morelli E, et al. Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation. Nephron 1998;79:137-41
   PubMed Web of Science ®Google Scholar
• Combe C, Morel D, de Precigout V, et al. Long-term control of hyperparathyroidism in advanced renal failure by low-phosphorus low-protein diet supplemented with calcium (without changes in plasma calcitriol). Nephron 1995;70:287-95
   PubMed Web of Science ®Google Scholar
• Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin J Am Soc Nephrol 2009;4:1370-3
   PubMed Web of Science ®Google Scholar
• Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 2008;88:1511-18
   PubMed Web of Science ®Google Scholar
• Sherman RA, Mehta O. Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources. Am J Kidney Dis 2009;54:18-23
   Google Scholar
• Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619-37
   PubMed Web of Science ®Google Scholar
• Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5:286-91
   PubMed Web of Science ®Google Scholar
• Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407-15
   PubMed Web of Science ®Google Scholar
• Koizumi M, Komaba H, Nakanishi S, et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012;27:784-90
   PubMed Web of Science ®Google Scholar
• Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-71
   PubMed Web of Science ®Google Scholar
• Messa P, Macario F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45
   PubMed Web of Science ®Google Scholar
• Zitt E, Jager C, Rosenkranz AR, et al. Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study. Wien Klin Wochenschr 2011;123:45-52
   Google Scholar
• Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008;3:1718-25
   PubMed Web of Science ®Google Scholar
• Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li M, You L, et al. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS One 2012;7:e48070
   PubMed Web of Science ®Google Scholar
• Investigators ET, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94
   PubMed Web of Science ®Google Scholar
• Garside R, Pitt M, Anderson R, et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007;22:1428-36
   PubMed Web of Science ®Google Scholar
• Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007;49:801-13
   PubMed Web of Science ®Google Scholar
• Moe SM, Thadhani R. What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? Curr Opin Nephrol Hypertens 2013;22:651-5
   PubMed Web of Science ®Google Scholar
• Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005;46:58-67
   PubMed Web of Science ®Google Scholar
• Collins MT, Skarulis MC, Bilezikian JP, et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998;83:1083-8
   PubMed Web of Science ®Google Scholar
• Flye MW, Brennan MF. Surgical resection of metastatic parathyroid carcinoma. Ann Surg 1981;193:425-35
   Google Scholar
• Padmanabhan H. Cinacalcet in the treatment of intractable hypercalcemia following two neck exploration surgeries for primary hyperparathyroidism. South Med J 2010;103:272-5
   Google Scholar
• Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:351-65
   PubMed Web of Science ®Google Scholar
• Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008;93:3462-70
   PubMed Web of Science ®Google Scholar
• Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2306-12
   PubMed Web of Science ®Google Scholar
• Luigi P, Chiara FM, Laura Z, et al. Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. Int J Endocrinol 2012;2012:408295
   PubMed Web of Science ®Google Scholar
• Weber T, Eberle J, Messelhauser U, et al. Parathyroidectomy, elevated depression scores, and suicidal ideation in patients with primary hyperparathyroidism: results of a prospective multicenter study. JAMA Surg 2013;148:109-15
   PubMed Web of Science ®Google Scholar
• Udelsman R, Pasieka JL, Sturgeon C, et al. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:366-72
   PubMed Web of Science ®Google Scholar
• Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-9
   PubMed Web of Science ®Google Scholar
• Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41
   PubMed Web of Science ®Google Scholar
• Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009;94:4860-7
   PubMed Web of Science ®Google Scholar
• Sloand JA, Shelly MA. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am J Kidney Dis 2006;48:832-7
   PubMedGoogle Scholar
• Horjus C, Groot I, Telting D, et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J Pediatr Endocrinol Metab 2009;22:741-9
   PubMed Web of Science ®Google Scholar
• Akinci B, Comlekci A, Tankurt E. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis. Exp Clin Endocrinol Diabetes 2009;117:142-5
   PubMed Web of Science ®Google Scholar
• Fanari Z, Kadikoy H, Haque W, et al. Medical management of primary hyperparathyroidism with concomitant multiple myeloma. Intern Med 2010;49:581-4
   PubMed Web of Science ®Google Scholar
• Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2766-72
   PubMed Web of Science ®Google Scholar
• Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol 2010;2010:906163
   PubMed Web of Science ®Google Scholar
• Filopanti M, Verga U, Ermetici F, et al. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur J Endocrinol 2012;167:157-64
   PubMed Web of Science ®Google Scholar
• Rasmussen AQ, Jorgensen NR, Schwarz P. Clinical and biochemical outcomes of cinacalcet treatment of familial hypocalciuric hypercalcemia: a case series. J Med Case Rep 2011;5:564
   Google Scholar
• Alon US, VandeVoorde RG. Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia. Pediatr Nephrol 2010;25:1747-50
   Google Scholar
• Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004;19:1281-7
   PubMed Web of Science ®Google Scholar
• Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002;13:551-8
   PubMed Web of Science ®Google Scholar
• Dumoulin G, Hory B, Nguyen NU, et al. No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997;29:746-53
   PubMed Web of Science ®Google Scholar
• Sprague SM, Belozeroff V, Danese MD, et al. Abnormal bone and mineral metabolism in kidney transplant patients – a review. Am J Nephrol 2008;28:246-53
   PubMed Web of Science ®Google Scholar
• Naylor KL, Li AH, Lam NN, et al. Fracture risk in kidney transplant recipients: a systematic review. Transplantation 2013;95:1461-70
   PubMed Web of Science ®Google Scholar
• Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007;21:558-66
   PubMed Web of Science ®Google Scholar
• Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005;5:1934-41
   PubMed Web of Science ®Google Scholar
• Cohen JB, Gordon CE, Balk EM, Francis JM. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis. Transplantation 2012;94:1041-8
   PubMed Web of Science ®Google Scholar